ID 405138300 · FY 2018–2024 · 7 years
კომპანიის ძირითად საქმიანობას წარმოადგენს მედიკამენტებით და სამედიცინო სახარჯი მასალებით საბითუმო ვაჭრობა.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Ratio | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Margins | |||||||
| Gross Margin | 34.8% | 31.3% | 30.2% | 31.4% | 31.7% | 36.1% | 34.6% |
| EBITDA Margin | 20.5% | 16.4% | 20.6% | 23.6% | 20.4% | 25.7% | 25.4% |
| EBITDAR | 533 | 441 | 742 | 1,120 | 1,083 | 1,187 | 1,443 |
| EBITDAR Margin | 22.6% | 18.6% | 22.2% | 24.9% | 22.3% | 27.5% | 26.6% |
| EBIT Margin | 20.3% | 16.1% | 20.4% | 23.5% | 20.2% | 25.6% | 25.3% |
| Net Profit Margin | 19.3% | 11.4% | 15.6% | 23.5% | 20.8% | 24.3% | 23.5% |
| Operating Expense % of Sales | 14.3% | 14.9% | 9.6% | 7.8% | 11.3% | 10.4% | 9.2% |
| Returns | |||||||
| Return on Assets (ROA) | 20.5% | 14.1% | 23.1% | 33.9% | 26.7% | 25.5% | 25.6% |
| Return on Equity (ROE) | 21.5% | 14.5% | 46.7% | 48.6% | 31.8% | 27.2% | 26.8% |
| ROIC [EBIT / Invested Capital] | 25.5% | 21.4% | 36.1% | 41.1% | 31.4% | 29.0% | 29.2% |
| Leverage & liquidity | |||||||
| Debt-to-Assets | 0.0% | 0.0% | 35.2% | 14.8% | 0.8% | 0.1% | 0.1% |
| Debt-to-Equity | 0.00x | 0.00x | 0.71x | 0.21x | 0.01x | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.00x | 0.00x | 1.16x | 0.44x | 0.03x | 0.00x | 0.00x |
| Equity-to-Assets | 95.5% | 97.3% | 49.4% | 69.7% | 84.1% | 93.5% | 95.6% |
| Net Debt | -247 | -87 | 770 | 392 | -58 | -40 | -64 |
| Cash & Equivalents | 247 | 87 | 28 | 71 | 88 | 44 | 69 |
| Total Debt | N/A | N/A | 797 | 463 | 31 | 4 | 4 |
| Efficiency & working capital | |||||||
| Inventory Turnover | N/A | 1.80x | 2.58x | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | 203.3 | 141.6 | N/A | N/A | N/A | N/A |
| Receivables Turnover | 1.93x | 2.77x | 2.62x | 2.57x | 2.11x | 1.67x | 1.91x |
| Days Sales Outstanding (DSO) | 188.7 | 131.7 | 139.2 | 142.0 | 173.1 | 219.1 | 191.0 |
| Payables Turnover | 15.74x | 36.76x | 6.76x | 6.42x | 5.82x | 10.47x | 17.09x |
| Days Payable Outstanding (DPO) | 23.2 | 9.9 | 54.0 | 56.8 | 62.7 | 34.9 | 21.4 |
| Cash Conversion Cycle | 165.5 days | 325.1 days | 226.9 days | 85.1 days | 110.4 days | 184.2 days | 169.7 days |
| Asset Turnover | 1.06x | 1.23x | 1.47x | 1.44x | 1.28x | 1.05x | 1.09x |
| Cash flow & dividends | |||||||
| Operating Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow (OCF − Capex proxy) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Conversion (OCF / EBITDA) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in ₾ '000. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.
Ownership & directors from companyinfo.ge (public corporate registry).